Latest Breaking News On - South korea based - Page 7 : vimarsana.com

CS5001 is the first known ROR1 antibody-drug conjugate (ADC) to demonstrate clinical anti-tumor activity in both solid tumors and lymphomas, and among the top two globally in clinical development. First-in-human study data show that CS5001 is well tolerated with promising anti-tumor activity at various dose levels in heavily pretreated, advanced solid tumors and lymphomas. Dose escalation in the.

South koreaUnited statesRepublic of koreaAmerican society of clinical oncologyCstone pharmaceuticalsLigachem biosciences incAmerican societyClinical oncologyCentral daylight timeLigachem biosciencesSouth korea based